The GEM Study: What the Largest Ginkgo Trial Taught Us About Dementia Prevention

The GEM Study: What the Largest Ginkgo Trial Taught Us About Dementia Prevention

For decades, ginkgo biloba sat on pharmacy shelves with an implied promise: take it daily, protect your memory, hold off dementia. The ginkgo biloba dementia study that finally put that promise to a real test was the Ginkgo Evaluation of Memory trial, known as the GEM study. It enrolled more than 3,000 older adults and followed them for years.

The answer it produced was not the one the supplement industry wanted.

Ginkgo did not prevent dementia. It did not slow cognitive decline. And the way researchers reached that conclusion is a useful lesson in how to read health claims that sound too good to walk past.

Key Takeaways

• The GEM study (ginkgo evaluation of memory) was the largest randomized trial of ginkgo for dementia prevention, with 3,069 participants.
• Over a median of 6.1 years, ginkgo (EGb 761, 120 mg twice daily) did not reduce dementia or Alzheimer disease incidence.
• A follow-up analysis found no effect on the rate of cognitive decline either.
• The trial answered "does ginkgo prevent dementia" with a clear no, and reshaped how clinicians view memory supplements.

What the GEM Study Actually Was

The GEM study was a randomized, double-blind, placebo-controlled trial built to answer one question: can ginkgo biloba prevent dementia in older adults? The GEM Study was a randomized, double-blind, placebo-controlled clinical trial of G. biloba for the prevention of dementia conducted at six academic medical centers across the US between 2000 and 2008.

This was not a small pilot. The GEM study is the largest randomized controlled trial of G biloba to report on outcomes to date. The scale matters. Smaller, shorter studies had hinted at benefits, but they lacked the size and follow-up to settle the question.

Participants were community-dwelling adults, most with normal cognition and some with mild cognitive impairment (MCI). Strengths of this study include the large number of randomized participants (n=3069), long duration of follow-up (median of 6 years), and breadth of the neuropsychological evaluation.

The intervention used a standardized extract called EGb 761, the same formulation behind most ginkgo dementia research. The dose was 120 mg, taken twice a day.

Does Ginkgo Prevent Dementia? The Primary Result

Ginkgo did not prevent dementia. That is the headline of the EGb 761 dementia data, and it came from the trial's main 2008 publication.

In this study, G biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI.

The numbers leaned the wrong way, in fact. The overall dementia rate was 3.3 per 100 person-years in participants assigned to G biloba and 2.9 per 100 person-years in the placebo group.

The statistical test confirmed no protective effect. The hazard ratio (HR) for G biloba compared with placebo for all-cause dementia was 1.12 (95% confidence interval [CI], 0.94-1.33; P=.21) and for AD, 1.16 (95% CI, 0.97-1.39; P=.11).

A hazard ratio above 1.0 means the ginkgo group did slightly worse, not better. The confidence interval crosses 1.0, so the honest read is simple: no benefit. Ginkgo also failed the people most at risk. G biloba also had no effect on the rate of progression to dementia in participants with MCI.

The Follow-Up: No Effect on Cognitive Decline Either

A second question remained after 2008. Even if ginkgo did not stop dementia outright, could it slow the slower, everyday erosion of memory and thinking? The research team published a follow-up analysis in JAMA in 2009 to find out.

The result was the same. According to the PubMed record of the 2009 analysis, the trial ran across six academic medical centers between 2000 and 2008 with a median follow-up of 6.1 years.

As the ScienceDaily summary of the findings reported, the authors wrote that they found no evidence ginkgo slows the rate of cognitive decline in older adults, and noted the results lined up with previous smaller studies and the 2009 Cochrane review.

The full analysis in PMC examined memory, language, attention, visuospatial abilities, and executive function. Ginkgo moved none of them.

Why the GEM Study Still Matters

A well-run negative result is one of the most valuable things in medicine. The GEM trial was big, long, blinded, and used the standardized extract sold to consumers. There was no easy excuse to dismiss it.

Before GEM, the case for ginkgo rested on a patchwork of smaller trials with mixed quality. The ginkgo prevention trial logic was reasonable on paper. Ginkgo affects blood flow and has antioxidant properties, so a memory benefit seemed plausible. Plausible is not the same as proven.

GEM is why most major clinical guidelines no longer recommend ginkgo for preventing dementia. It is also a clean case study in survivorship bias, the trap of believing a supplement works because the people taking it for years happen to feel fine.

The Lesson for Any Supplement Claim

When a product claims to prevent a disease over years or decades, ask for the trial that tested exactly that. Not a lab study. Not a six-week memory quiz. A long, randomized, placebo-controlled trial in real people. Ginkgo had its trial. The data spoke.

How Ginkgo's Evidence Compares

Here is an honest snapshot of what the leading "memory and focus" options are actually backed to do. Long-horizon dementia prevention and short-term focus are two different claims with two different evidence bars.

The point of the table is the column on the right versus the column in the middle. A compound can be useless for preventing dementia and still useful for getting through a hard afternoon of work. Those are separate questions.

For more on the focus side of that equation, see our breakdowns of how caffeine and L-theanine work together and what actually causes the afternoon caffeine crash.

Frequently Asked Questions

What was the GEM study?

The GEM study, short for Ginkgo Evaluation of Memory, was a large randomized controlled trial testing whether ginkgo biloba could prevent dementia. It ran across multiple US academic medical centers from 2000 to 2008 and enrolled 3,069 older adults. Participants took either ginkgo extract EGb 761 at 120 mg twice daily or a placebo, and researchers followed them for a median of about six years to track dementia diagnoses and cognitive change.

Does ginkgo prevent dementia?

No. The GEM trial, the largest study to test this directly, found that ginkgo at 120 mg twice daily did not reduce the overall rate of dementia or Alzheimer disease, in people with normal cognition or those with mild cognitive impairment. The dementia rate was actually slightly higher in the ginkgo group than the placebo group, though the difference was not statistically meaningful.

Did ginkgo at least slow cognitive decline?

No. A 2009 follow-up analysis of the same GEM participants looked at memory, language, attention, visuospatial ability, and executive function. Ginkgo showed no effect on the rate of decline in any of those areas over the 6.1-year median follow-up. The authors concluded there was no evidence ginkgo slows cognitive decline in older adults.

What is EGb 761?

EGb 761 is a standardized ginkgo biloba leaf extract used in most serious ginkgo research, including the GEM study. Standardization means the active compounds are present at consistent levels from batch to batch. Using EGb 761 mattered because it removed the "wrong product" excuse. The GEM trial tested the same well-characterized extract that consumers were buying, and it still showed no dementia benefit.

Why do people still take ginkgo if it doesn't work?

A few reasons. Ginkgo has a long history in traditional medicine, marketing still implies memory benefits, and people who take it for years and feel fine credit the supplement rather than chance. That belief is a textbook case of survivorship bias. The GEM data are the cleanest counterargument: a large, long, placebo-controlled trial that found no prevention benefit.

Is ginkgo dangerous?

For most people ginkgo is generally well tolerated, but it is not free of concerns. It can thin the blood and may interact with anticoagulant medications, so it is worth discussing with a clinician before use. This article is informational and not medical advice. The bigger issue highlighted by GEM is not safety but effectiveness: it simply did not deliver the prevention benefit people expected.

Reading Trials Honestly Is the Whole Point

The GEM study did something rare and useful. It took a popular claim, tested it at scale, and reported a clean answer even though that answer disappointed an entire product category. Ginkgo does not prevent dementia, and it does not slow cognitive decline.

The broader takeaway is about how you evaluate any cognitive product. Match the claim to the evidence. A long-horizon prevention promise needs a long-horizon trial. A short-term focus claim needs short-term focus data. Conflating the two is how good marketing outruns good science.

Why We Won't Promise You a Decade of Protection

At Roon, we read trials like GEM as a warning label for our own marketing. The lesson is simple: claim only what your evidence supports.

So we are direct about it. Roon is built for acute, sustained focus, not long-term dementia prevention. Our formula is four ingredients with a clear job: 80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine (Dynamine), and 5 mg theacrine (TeaCrine), delivered in a sublingual pouch designed for a 5 to 10 minute onset and 6 to 8 hours of steady focus without the jitters or crash.

Roon is not a substitute for sleep, exercise, or anything your doctor recommends for long-term brain health, and it makes no prevention claims it cannot back up. If you want clean focus for the work in front of you today, that is the thing we can stand behind. Try Roon for the afternoon you actually need to get through.

Written by Roon Team